Special Issue

Current and Emerging Utility of Liquid Biopsy in Cancers. More than Surrogate Biomarkers

Message from the Guest Editors

Liquid biopsy has emerged as a reliable tool for tumor surveillance, studying disseminated tumor cells in bone marrow and circulating tumor cells in peripheral blood and providing crucial insights into cancer biology and the metastatic process. We are pleased to invite you to participate in this Special Issue that will focus on the state of the art and the latest findings on circulating tumor biomarkers, circulating tumor cells (CTCs), tumor hybrid cells (THCs), as well as ctDNA and ctRNA (coding and noncoding) and protein analysis, and clinical evidence regarding the implementation of liquid biopsy in clinical practice. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

- Implication of liquid biopsy in cancer diagnosis, prognosis, and clinical management;
- More than circulating tumor cells in blood sample characterization:
- DNAs, RNAs, and proteins as cancer biomarkers in biofluids;
- Liquid biopsy approximations in immunotherapy response prediction.

We look forward to receiving your contributions.

Guest Editors

Dr. Marta Dueñas

Molecular and Translational Oncology Unit, Department of Biomedical Innovation at CIEMAT, Madrid, Spain

Dr. Rodrigo Toledo

Gastrointestinal Tumor Group, Department of Oncology, Vall d'Hebron Institute of Oncology, Barcelona, Spain

Deadline for manuscript submissions

closed (30 September 2023)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/104049

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

